Champions Oncology, Inc.는 미국 전역에서 종양학 의약품의 개발을 간소화하고 암 치료를 개인화하기 위해 설계된 최첨단 기술 제품과 서비스를 개발하고 상용화하는 데 전념하고 ...
예상 EPS $0.02 · 매출 $16.37M · 1 명의 애널리스트
예상 EPS $0.08 · 매출 $18.13M · 1 명의 애널리스트
예상 EPS $0.10 · 매출 $65.26M · 1 명의 애널리스트
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $59.4M | +4.4% | -16.4% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-1.2M | -125.0% | -161.3% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +48.0% | -4.3% | +8.9% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -1.9% | -122.5% | -303.8% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -2.0% | -124.0% | -212.7% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-5.0M | -172.0% | -62.6% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -8.5% | -169.0% | -94.6% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 114.5% | -29.2% | +0.0% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 0.96x | +2.9% | -1.2% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $27.0M | -16.6% | -5.1% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -0.08 vs 0.12 | -166.7% | -0.05 vs -0.05 | +6.2% |
| 매출 서프라이즈 | $59.4M vs $58.5M | +1.5% | $13.8M vs $12.9M | +7.4% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Nov 5, 2025 | Breitfeld Philip P. | director | Option to purchase Common Stock | A | 13,790 | $6.80 |
| Nov 5, 2025 | SIDRANSKY DAVID | director | Option to purchase Common Stock | A | 21,216 | $6.80 |
| Nov 5, 2025 | Mendelson Daniel Newman | director | Option to purchase Common Stock | A | 13,790 | $6.80 |
| Nov 5, 2025 | TOBIN SCOTT R | director, 10 percent owner: | Option to purchase Common Stock | A | 25,460 | $6.80 |
| Nov 5, 2025 | ACKERMAN JOEL | director | Option to purchase Common Stock | A | 21,216 | $6.80 |
Operator: Good day, everyone, and welcome to the Champions Oncology Fourth Quarter Fiscal Year 2026 Earnings Call. It is now my pleasure to hand the floor over to your host, Robert Brainin, CEO of Champions Oncology. Sir, the floor is yours. Thank you. Robert Brainin: Good afternoon, and thank you for joining our fiscal 2026 year-end earnings call. I'm Rob Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Actual results may differ materially, and you can find more information in our filings with the SEC. I'd like to begin by referring back to what I said shortly after stepping into this role in late August 2025. I said then that we will build on the progress the company has made over recent years, stay focused on positive adjusted EBITDA for the year and at the same time, keep investing in our 2 growth vectors, data and Corellia, with the returns on those investments coming in later quarters and years as well as continuing to invest in our TOS business, especially around growth areas like the radioligand platform. I'm pleased to say our execution against that plan held up well. In fiscal 2026, we delivered record annual revenue and met our commitment to full year positive adjusted EBITDA, including positive adjusted EBITDA in each of the 4 quarters on its own, the first time that has happened since fiscal 2022, driven by real strength in our core services business. Our data business did not repeat its fiscal 2025 revenue, but the comparison is less telling than it looks, and I'll come back to why later in my remarks. And we invested across the organization to build for the next phase of growth. That combination produced a record top line as well as positive adjusted EBITDA alongside a GAAP net loss that reflects those deliberate investments. Our translational oncology services business had its strongest year in the company's history. Services revenue grew to a record $58.7 million, up approximately 12% over the prior year as previously booked studies converted well and our PDX Bank continued to differentiate us in a market where model quality and characterization matter more every year. I want to thank our operations team again who delivered that growth without material additions to headcount, which is the operating leverage we've been describing starting to show up in the numbers. As we said before, quarterly results can vary, primarily due to the timing of study completions. So we evaluate the business on an annual basis. After this year's strong conversion, we'd expect services growth to moderate to a more normalized pace in the near term. The underlying demand environment is healthy, and our focus is on continuing to expand bookings and the future pipeline of work. In terms of data, the year-over-year comparison does not tell the complete story. Data license revenue was approximately $800,000 for fiscal 2026 …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Ronnie Morris | Executive Chair | USD 810,699 | — | 1966 | Active |
Robert Brainin | Chief Executive Officer & Director | USD 516,423 | Male | 1972 | Active |
David Barry Miller | Chief Financial Officer | USD 340,000 | Male | 1969 | Active |
Maria Mancini | Chief Operating Officer | — | — | — | Active |
Marianna Zipeto | Executive Vice President of Growth, Strategy & Enablement | — | — | — | Active |
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026. Fourth Quarter and Other Financial Highlights: Record annual revenue of $59.4 million Fourth quarter revenue of $13.8 million Fourth quarter oncology services margin of 51% Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year Adjusted EBITDA income all four quarters in FY 2026 Continued investment in radiopharmaceuticals, the data platform and commercial organization Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth.
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
